Profile data is unavailable for this security.
About the company
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
- Revenue in USD (TTM)32.53bn
- Net income in USD4.23bn
- Incorporated1986
- Employees26.70k
- LocationAmgen IncOne Amgen Center DriveTHOUSAND OAKS 91320United StatesUSA
- Phone+1 (805) 447-1000
- Fax+1 (805) 447-1010
- Websitehttps://www.amgen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zoetis Inc | 9.15bn | 2.43bn | 79.73bn | 14.10k | 33.22 | 15.25 | 27.14 | 8.71 | 5.32 | 5.32 | 20.02 | 11.59 | 0.6431 | 1.06 | 6.86 | 649,078.00 | 17.13 | 14.47 | 19.38 | 17.18 | 70.13 | 69.77 | 26.64 | 25.77 | 2.27 | 18.96 | 0.5567 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
| Gilead Sciences, Inc. | 28.30bn | 126.00m | 111.86bn | 18.00k | 1,068.70 | 6.05 | 38.87 | 3.95 | 0.084 | 0.084 | 22.61 | 14.83 | 0.4842 | 3.56 | 6.04 | 1,572,167.00 | 0.1933 | 6.74 | 0.242 | 8.12 | 77.80 | 79.14 | 0.3993 | 16.95 | 1.10 | 17.00 | 0.5584 | 81.22 | -0.6048 | 4.15 | 23.37 | 0.7436 | -8.74 | 5.64 |
| Bristol-Myers Squibb Co | 47.44bn | -7.26bn | 118.10bn | 34.10k | -- | 6.89 | 40.21 | 2.49 | -3.60 | -3.60 | 23.38 | 8.45 | 0.513 | 3.97 | 5.12 | 1,391,056.00 | -7.84 | 3.05 | -10.45 | 3.76 | 75.87 | 76.13 | -15.28 | 7.69 | 1.09 | 11.30 | 0.7431 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Pfizer Inc | 60.11bn | 4.27bn | 142.41bn | 88.00k | 33.79 | 1.54 | 12.72 | 2.37 | 0.7438 | 0.7399 | 10.57 | 16.29 | 0.2767 | 1.60 | 4.71 | 683,079.60 | 1.98 | 8.20 | 2.39 | 10.40 | 70.82 | 69.34 | 7.16 | 22.68 | 0.729 | -- | 0.4225 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Amgen Inc | 32.53bn | 4.23bn | 155.83bn | 26.70k | 37.09 | 20.70 | 15.89 | 4.79 | 7.82 | 7.82 | 60.33 | 14.00 | 0.3587 | 2.08 | 4.83 | 1,218,502.00 | 4.66 | 10.36 | 5.87 | 13.06 | 60.48 | 75.41 | 13.00 | 26.51 | 0.9553 | 2.62 | 0.8892 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 49.86m | 9.28% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 29.32m | 5.46% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 28.35m | 5.28% |
| PRIMECAP Management Co.as of 30 Sep 2024 | 14.26m | 2.65% |
| Geode Capital Management LLCas of 30 Sep 2024 | 12.12m | 2.26% |
| Charles Schwab Investment Management, Inc.as of 30 Sep 2024 | 10.53m | 1.96% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2024 | 8.72m | 1.62% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 8.56m | 1.59% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 5.81m | 1.08% |
| BlackRock Advisors (UK) Ltd.as of 30 Sep 2024 | 5.72m | 1.06% |
